Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Update

Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a large drop in short interest in July. As of July 15th, there was short interest totalling 4,340,000 shares, a drop of 18.1% from the June 30th total of 5,300,000 shares. Approximately 8.2% of the company’s stock are sold short. Based on an average daily volume of 817,600 shares, the days-to-cover ratio is currently 5.3 days.

Wall Street Analyst Weigh In

RGLS has been the topic of several recent analyst reports. Canaccord Genuity Group increased their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. StockNews.com assumed coverage on Regulus Therapeutics in a research report on Tuesday, April 16th. They set a “sell” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Regulus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RGLS. Victory Capital Management Inc. raised its position in Regulus Therapeutics by 16.5% in the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 38,529 shares in the last quarter. Vivo Capital LLC purchased a new stake in shares of Regulus Therapeutics during the 1st quarter worth approximately $14,400,000. CVI Holdings LLC purchased a new position in Regulus Therapeutics in the 1st quarter valued at approximately $4,050,000. Vanguard Group Inc. increased its stake in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 453,784 shares in the last quarter. Finally, NEA Management Company LLC purchased a new position in Regulus Therapeutics in the 1st quarter valued at approximately $18,627,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Performance

Shares of NASDAQ RGLS traded up $0.02 during midday trading on Friday, reaching $1.78. 1,509,376 shares of the company were exchanged, compared to its average volume of 835,089. The stock has a fifty day simple moving average of $2.02 and a 200 day simple moving average of $1.98. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.14). On average, equities research analysts expect that Regulus Therapeutics will post -0.59 earnings per share for the current year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.